Rina Das, Ph.D.
Center to Reduce Cancer Health Disparities
National Cancer Institute
6116 Executive Blvd., Suite 602, Rm 6043
Rockville, MD 20852
phone: (301) 496-8090
fax: (301) 435-9225
Rina Das, Ph.D., is a program director at the Disparities Research Branch within the Center to Reduce Cancer Health Disparities at the National Cancer. Dr. Das manages disparity research programs and administers to grant programs designed to improve diversity of cancer research within the workforce through training, career development, the Minority Institution/Cancer Center partnership program, and investigator initiated programs.
Prior to her appointment at National Cancer Institute (NCI), Dr. Das served as Scientific Review Officer at the National Institute of Heart Lung and Blood Institute, National Institutes of Health in Bethesda, MD. Her responsibilities included reviewing different grant mechanisms including investigator initiated, center grants, career development awards, and loan repayment programs. She was a member of the Data Access Committee (DAC) for the NHLBI Supported Genome Wide Association Studies, the Genetics and Genomics Working Group, and the NHLBI Training Committee. She also co-chaired the working group on Computational Models for Analyzing Genotype-Phenotype Associations in Rare Diseases at NHLBI. The report is published at http://www.nhlbi.nih.gov/meetings/workshops/gpa_rarediseases.htm.
Dr. Das received her Ph.D. in biochemistry from Jawaharlal Nehru University, Delhi, India. Her postdoctoral training in breast cancer research at the Laboratory of Tumor Immunology and Biology at NCI, NIH. She also served as a Group Leader at the Walter Reed Army Institute of Research at the Department of Molecular Pathology where she was involved with genomics research in the fields of breast cancer, prostate cancer, and host immune responses. Her research interests include genomics, cancer biology, bioinformatics, basic and preclinical research in host immune responses. Dr. Das has over 40 scientific publications and 2 patents in the field of genomics.
M. Jett, R. Das and R. Neill (Patent # US 7,175,981 B2) Method of diagnosing stage or aggressiveness of breast and prostate cancer based on levels of fatty acid binding proteins. Awarded Feb, 2007.
R. Das, C. Mendis and M. Jett (Patent # US 6,316,197 B1) Diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes. Awarded Nov, 2001.
Selected Publications and Presentations
Moore B. and Das R. (2008) Working Group Report on Computational Models for Analyzing Genotype-Phenotype Associations in Rare Diseases at NHLBI
Das R, et al. (2008) Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells. BMC Infect Dis. 2008 Jul 30;8:104.
Das R, Dhokalia A, Huang X, Hammamieh R, Lindler L. and Marti Jett. (2007). Study of proinflammatory responses induced by Yersinia pestis in human monocytes using cDNA arrays. Genes and Immunity 8:308-319.
Hammamieh R, Chakraborty N, Miller SA, Waddy E, Barmada M, Das R, Peel SA, Day AA, Jett M. (2007). Differential effects of omega-3 and omega-6 fatty acids on gene expression in breast cancer cells. Breast Cancer Res. and Treatment. 2007; Jan; 101:7-16. Epub 2006.
Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M. (2005). Expression patterns of fatty acid binding proteins in breast cancer cells. J Exp Ther Oncol. 2005;5(2):133-43.
Hammamieh R, Chakraborty N, Das R, Jett M. (2004). Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro. J Exp Ther Oncol. 2004 Oct;4(3):195-202.